Undisclosed Immunometabolism Program(s)

About Inapill

Inapill is pioneering a novel approach to inflammation by developing oral small molecules that target immunometabolism, aiming to simultaneously suppress multiple disease-driving cytokines. The company's platform is inspired by research on sex differences in inflammation and seeks to overcome the limitations of existing biologics, such as cytokine redundancy, immunogenicity, and poor patient compliance due to injectable administration. Backed by the venture studio General Inception, Inapill is in the discovery and preclinical development stage, building a team with deep expertise in immunology, metabolism, and protein biochemistry to advance its pipeline.

Therapeutic Areas

Other Inflammatory/Autoimmune Diseases Drugs